HOME > COLUMN

    COLUMN

    COMMENTARY

    2019 Likely to Herald Burst of “Regenerative Medicine” Approvals
    By Shinya Sato

    As 2019 rolls in, we expect to see a flurry of approvals in the Japanese regenerative medicine arena, with regulatory decisions anticipated by the end of the year for Novartis Pharma’s CAR-T therapy and many more products, which could bring…

    Takeda’s £46 Billion Shire Buyout

    Takeda Completes £46 Billion Shire Acquisition

    Takeda Pharmaceutical completed the £46 billion acquisition of Shire on January 8, vaulting itself into the top 10 league of…

    COLUMN

    Expat Truths from the Japanese Medical Device World
    By Gregory Ng

    To many people, Japan has always been one of the world’s most advanced economies and a market of rich opportunities with one of the top healthcare systems worldwide.Add a rapidly changing demographic, a declining workforce, and the constant challenges of…

    TRENDS

    Generic Industry at Crossroads: Companies Face Pressing Need to Boost Profitability ahead of FY2020
    By Reiji Anasako

    While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…